Testosterone replacement therapy (TRT) is one of the most widely discussed and widely used hormone protocols in existence. Whether prescribed through a clinic or self-administered, the core pharmacology is the same: exogenous testosterone is introduced to restore circulating levels to a physiological range, replacing what the body is no longer producing sufficiently on its own.
This guide covers the fundamentals — the different testosterone esters available, how dosing frequency affects blood level stability, what the first 12 weeks on TRT typically look like, and which bloodwork markers matter for ongoing monitoring. It is written as an observational reference, not medical advice.
TRT is a medical intervention. The information in this guide is educational and observational. Testosterone is a controlled substance in most jurisdictions. Baseline bloodwork confirming low testosterone (hypogonadism) is the standard clinical prerequisite before initiating TRT. Self-prescribing without baseline labs means operating without reference values — making it difficult to assess whether levels are optimized or to detect emerging issues.
What Is TRT?
Testosterone replacement therapy refers specifically to the administration of exogenous testosterone with the goal of restoring blood testosterone levels to a normal physiological range — typically 400-900 ng/dL total testosterone for adult males, though the precise "optimal" range is individual and debated. The distinction matters: TRT aims to replace what is missing, not to exceed natural levels.
The most common populations using TRT include men with primary hypogonadism (testicular dysfunction — the testes don't produce sufficient testosterone despite adequate signaling), secondary hypogonadism (pituitary or hypothalamic dysfunction — the brain doesn't send the right signals to the testes), and age-related decline (testosterone production naturally decreases roughly 1-2% per year after age 30, and some men become symptomatic).
Symptoms commonly associated with low testosterone include persistent fatigue despite adequate sleep, reduced libido, difficulty building or maintaining muscle mass, increased body fat (particularly abdominal), low mood or irritability, brain fog, and reduced motivation. These symptoms overlap significantly with other conditions — which is why bloodwork, not symptom checklists, is the diagnostic standard.
TRT is distinct from supraphysiological testosterone use (bodybuilding doses). The pharmacology is the same compound, but the dosing, goals, and monitoring differ substantially. TRT protocols typically use 100-200 mg/week of testosterone, while supraphysiological use can involve 500+ mg/week alongside other compounds. This guide addresses replacement-dose protocols only.
Testosterone Esters
Testosterone itself has a very short half-life in the body — roughly 10-100 minutes when injected as pure testosterone (suspension). To create a clinically useful medication with reasonable injection frequency, testosterone is attached to an ester — a chemical modification that slows its release from the injection depot into the bloodstream.
The ester does not change what the testosterone does once it is active. It only controls how quickly the testosterone is released. Longer esters = slower release = less frequent injection. The ester is cleaved off in the bloodstream, leaving identical bioactive testosterone regardless of which ester was attached.
| Ester | Half-Life | Typical Frequency | Notes |
|---|---|---|---|
| Testosterone Cypionate | ~8 days | 1-2x per week | Most commonly prescribed in the US. Slightly longer half-life than enanthate. Virtually interchangeable with enanthate at equivalent doses. |
| Testosterone Enanthate | ~4.5 days | 1-2x per week | Most commonly prescribed worldwide. The global standard for TRT. Slightly faster release than cypionate. |
| Testosterone Propionate | ~0.8 days | Every other day or daily | Very short ester. Produces sharp peaks and troughs. Rarely used for TRT due to injection frequency requirements. More common in performance contexts. |
| Testosterone Undecanoate | ~20+ days | Every 10-14 weeks | Brand name Nebido (injection) or Jatenzo (oral). Very long-acting. Less frequent injection but less precise dose titration. Used more commonly in European TRT clinics. |
For practical purposes, cypionate and enanthate are the two esters that dominate TRT protocols. They are functionally interchangeable — the pharmacokinetic difference between them is marginal. Most users and clinics select based on local availability and cost. Switching between them at equivalent doses does not require dose adjustment.
A compound's half-life is the time it takes for the blood concentration to drop to 50% of its peak. After one half-life, 50% remains. After two, 25%. After five half-lives, the compound is effectively cleared. This is why injection frequency matters — more frequent injections with shorter intervals produce more stable blood levels with less peak-to-trough variation. The half-life comparison chart visualizes this across all major compounds.
Typical TRT Protocols
The same weekly dose of testosterone produces very different blood level profiles depending on how frequently it is administered. More frequent, smaller injections produce more stable levels. Less frequent, larger injections produce wider swings between peak and trough. This peak-to-trough variation is one of the most important pharmacokinetic concepts in TRT.
| Protocol | Dose Example | Frequency | Level Stability | Notes |
|---|---|---|---|---|
| Once weekly | 150-200 mg | Every 7 days | Moderate | Simple schedule. Moderate peak-to-trough swing. The most common starting protocol at TRT clinics. |
| Twice weekly | 75-100 mg x2 | Every 3.5 days | Good | Cuts peak-to-trough variation roughly in half compared to once weekly. Increasingly the standard recommendation. Stable levels reduce estradiol conversion spikes. |
| Every other day | ~40-55 mg EOD | Every 2 days | Very good | Near-flat blood level curve. Popular among users who are sensitive to fluctuations. SubQ-friendly due to small volumes per injection. |
| Every 2 weeks | 200-300 mg | Every 14 days | Poor | Commonly prescribed but pharmacokinetically suboptimal. Produces large peaks (often supraphysiological) followed by deep troughs. Many users report mood and energy fluctuations. |
The trend in TRT management over the last decade has moved toward more frequent injection. The reason is straightforward: splitting the same total weekly dose across more injection points produces a flatter concentration curve. Flatter curves mean less time spent at supraphysiological peaks (where side effects are more likely) and less time in symptomatic troughs (where benefits fade).
A common optimization path looks like this: a user starts on 150 mg once weekly, gets bloodwork showing high peaks and low troughs with symptoms returning late in the week, then switches to 75 mg twice weekly on the same total dose. The trough rises, the peak drops, and subjective symptoms stabilize — without changing the total amount of testosterone administered.
The First 12 Weeks
Testosterone replacement is not an overnight intervention. Different physiological systems respond on different timelines, and the compound itself needs time to reach pharmacokinetic steady state — the point where administration rate equals elimination rate and blood levels stabilize. For testosterone enanthate, steady state is reached in approximately 3 weeks. For testosterone cypionate, approximately 5-6 weeks.
The following timeline reflects what is commonly reported in the literature and in user experience. Individual variation is significant — some users notice changes earlier, others later. Genetics, starting testosterone level, body composition, sleep quality, diet, and training all modulate the response.
Weeks 1-2: Building Levels
During the first two weeks, circulating testosterone levels are rising toward steady state but have not yet stabilized. Most users report little to no noticeable change during this window. The compound is accumulating in the system — each injection is adding to the levels from the previous one. This is the superposition principle in pharmacokinetics: repeat dosing before the previous dose is fully cleared creates a stacking effect that builds toward a stable plateau.
Weeks 3-4: Early Changes
The first subjective changes commonly reported around weeks 3-4 include improved energy levels, enhanced mood, increased libido, and better sleep quality. These are among the fastest-responding systems because they are directly sensitive to androgen receptor activation in the brain. Libido changes in particular tend to be noticeable early. Some users also report improved mental clarity and reduced brain fog.
Weeks 6-8: Body Composition Shifts
Measurable changes in body composition — increased lean mass, reduced fat mass — typically become detectable around weeks 6-8. Testosterone promotes protein synthesis and nitrogen retention in muscle tissue while simultaneously increasing lipolysis (fat mobilization). These are slower processes than mood and libido changes. Strength in the gym often increases noticeably during this window, particularly on compound movements.
Weeks 10-12: Approaching Full Effect
By weeks 10-12, the full spectrum of testosterone's effects is approaching its plateau. Body composition changes continue to accumulate. Recovery from training improves. Many users report this as the point where TRT "clicks" — the cumulative benefit of stable testosterone levels across multiple systems becomes clearly apparent in daily life. This is also the typical window for the first follow-up bloodwork to assess whether the dose needs adjustment.
These timelines are population averages. Some individuals respond faster, others slower. Factors that influence response speed include starting testosterone level (lower baseline = more dramatic change), age, body fat percentage (adipose tissue contains aromatase which converts testosterone to estrogen), sleep quality, stress levels, and training status. Two people on identical protocols can have meaningfully different experiences in the first 12 weeks.
Bloodwork on TRT
Bloodwork is the objective feedback mechanism for TRT. Subjective improvements matter — they are the reason people start TRT — but blood markers provide the data needed to optimize dosing, detect issues early, and confirm that the protocol is doing what it is intended to do.
A pre-TRT baseline blood panel is considered essential. Without it, there is no reference point to compare against. Baseline values establish where each marker starts, making it possible to attribute changes to the protocol rather than guessing. Many users who start without baseline labs report wishing they had them once optimization begins. The bloodwork timing guide covers when and how to schedule labs throughout a protocol.
| Marker | What It Measures | Typical Range | Why It Matters |
|---|---|---|---|
| Total Testosterone | All circulating testosterone (bound + free) | 400-900 ng/dL | The primary measure of whether the dose is producing physiological levels. Drawn at trough for accuracy. |
| Free Testosterone | Unbound, bioactive testosterone | 9-30 pg/mL | The fraction actually available to tissues. Can be low even with normal total T if SHBG is high. |
| Estradiol (E2) | Primary estrogen, converted from testosterone | 20-40 pg/mL | Aromatization of testosterone produces estradiol. Levels that are too high or too low both produce symptoms. Tracks with dose and frequency. |
| Hematocrit | Percentage of blood volume that is red blood cells | 42-52% | Testosterone stimulates erythropoiesis (red blood cell production). Elevated hematocrit increases blood viscosity. One of the most important safety markers on TRT. |
| PSA | Prostate-specific antigen | <4.0 ng/mL | Monitored to establish baseline and track prostate health over time. TRT does not cause prostate cancer but may stimulate growth of pre-existing tissue. |
| Lipid Panel | LDL, HDL, triglycerides, total cholesterol | Varies | Exogenous testosterone can reduce HDL (the protective fraction). Monitoring lipids is part of cardiovascular risk assessment on long-term TRT. |
| SHBG | Sex hormone-binding globulin | 20-60 nmol/L | Binds testosterone and makes it unavailable. High SHBG means more total T is needed to produce adequate free T. Low SHBG means free T may be disproportionately high relative to total. |
| Liver Panel | AST, ALT enzymes | 7-56 U/L | Injectable testosterone is not liver-toxic (unlike oral methylated steroids), but baseline liver values are useful for overall health tracking and ruling out pre-existing conditions. |
When to draw blood: The first follow-up panel is typically done at 6-8 weeks after starting TRT, timed as a trough draw — the blood sample is taken immediately before the next scheduled injection, capturing the lowest point in the dosing cycle. This gives the most conservative and reproducible measurement. Drawing at peak (24-48 hours post-injection) will show an inflated number that does not represent average circulating levels.
After the initial optimization period, most protocols move to bloodwork every 3-6 months for ongoing monitoring. Hematocrit in particular warrants consistent tracking, as testosterone-driven erythropoiesis is cumulative and can continue to increase red blood cell mass over months.
Common Concerns
Estradiol Management
Testosterone is converted to estradiol via the aromatase enzyme. This is a normal physiological process — estradiol is essential for bone density, cardiovascular health, cognitive function, and libido in men. The goal is not to eliminate estradiol but to keep it in a proportionate range relative to testosterone levels.
Symptoms commonly associated with elevated estradiol include water retention, moodiness, and sensitive breast tissue. Symptoms associated with low estradiol include joint pain, dry skin, low libido, and flat mood. More frequent injection schedules tend to produce more stable estradiol levels because they reduce the high testosterone peaks that drive aromatization.
Hematocrit Elevation
Testosterone stimulates the production of red blood cells (erythropoiesis) via erythropoietin. This is one of testosterone's well-documented physiological effects. For most TRT users, the increase is modest and stays within normal limits. However, some individuals — particularly those at higher doses, older users, or those with baseline hematocrit near the upper end — may see levels rise above the standard reference range.
Elevated hematocrit (polycythemia) increases blood viscosity, which is associated with increased cardiovascular workload. Regular monitoring via bloodwork is the standard approach to tracking this. Staying well-hydrated and monitoring trends over time allows early detection of any meaningful rise.
Fertility Considerations
Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. The body detects adequate circulating testosterone and reduces production of LH and FSH — the hormones that drive sperm production in the testes. This can significantly reduce sperm count, sometimes to zero (azoospermia). The effect is generally reversible after cessation, though recovery timelines vary from months to over a year.
For men who want to preserve fertility while on TRT, HCG (human chorionic gonadotropin) is commonly co-administered. HCG mimics LH and maintains intratesticular testosterone, which supports ongoing spermatogenesis. This is a standard protocol option at many TRT clinics for men of reproductive age.
Injection Route: IM vs SubQ for TRT
Intramuscular injection has been the traditional administration route for testosterone esters. However, subcutaneous injection has gained substantial traction for TRT specifically. Several studies have demonstrated comparable testosterone levels when TRT-dose testosterone is administered SubQ vs IM.
SubQ offers practical advantages for TRT: finer needles (27-30g vs 23-25g), more comfortable injection, more injection sites available, and less injection-site soreness. It works particularly well with frequent, small-volume injection protocols (e.g., EOD or twice weekly) where each injection volume is small. For larger single-dose protocols (e.g., 200 mg once weekly), IM remains more practical because SubQ injection of larger oil volumes can produce a noticeable subcutaneous depot. See the injection technique guide for detailed technique on both routes.
Tracking Your Protocol
TRT is a long-term commitment — for most users, it becomes an indefinite protocol. This makes consistent tracking particularly valuable. The two categories of data that matter most over time are objective bloodwork markers and subjective daily markers.
Objective data — testosterone levels, hematocrit, estradiol, lipids — provides the clinical picture. But these are sampled infrequently (every few months). In between blood draws, subjective daily tracking fills the gap: energy, mood, libido, sleep quality, recovery, and body composition changes form a granular day-to-day record that reveals patterns invisible in quarterly bloodwork.
The combination is powerful. If energy and mood decline at week 8 but testosterone trough levels are adequate on bloodwork, the issue may be elsewhere — sleep, stress, estradiol, or training load. If subjective markers are strong but hematocrit is trending up, the data supports a proactive conversation with a healthcare provider rather than waiting for symptoms. Tracking creates the context that makes each data point meaningful.
Understanding where your levels sit within the dosing cycle — whether you are building toward steady state, at peak, or approaching trough — provides the pharmacokinetic context that transforms raw numbers into actionable information. This is what level tracking for testosterone enanthate and testosterone cypionate is designed to show.
Frequently Asked Questions
How long does TRT take to work?
The timeline depends on which effects you are tracking. Energy, mood, and libido improvements are commonly reported within 3-6 weeks as testosterone levels reach steady state. Body composition changes — increased lean mass and reduced body fat — typically become measurable around weeks 8-12. Full effects on bone density, cardiovascular markers, and red blood cell production continue to develop over 6-12 months. The pharmacokinetic steady state of the compound itself is reached within 3-6 weeks depending on the ester, but the body's physiological adaptation to stable testosterone levels is a slower process.
Is SubQ or IM better for TRT?
Both routes produce comparable testosterone levels at TRT doses, and both are widely used. IM has a longer clinical history and produces slightly faster peak absorption. SubQ uses finer, shorter needles and is generally more comfortable — particularly well-suited to frequent injection schedules (twice weekly or every other day) where each injection volume is small. Many TRT clinics now offer SubQ as a standard option. The choice often comes down to personal preference, injection frequency, and volume per injection. There is no pharmacological reason to prefer one over the other at replacement doses.
Does TRT cause hair loss?
Testosterone does not directly cause hair loss. The mechanism involves its conversion to dihydrotestosterone (DHT) via the 5-alpha reductase enzyme. DHT is the androgen responsible for miniaturizing hair follicles in individuals with a genetic predisposition to androgenetic alopecia (male pattern baldness). If you carry the genetic variants for male pattern baldness, TRT may accelerate what would have occurred naturally. If you do not have the genetic predisposition, TRT does not initiate hair loss. Some users monitor hair density as part of their subjective tracking and discuss 5-alpha reductase inhibitors (e.g., finasteride) with their provider if acceleration is observed.
Does TRT affect fertility?
Yes — exogenous testosterone suppresses the HPG axis, reducing or eliminating endogenous production of LH and FSH, which are required for sperm production. Sperm count can drop significantly, sometimes to zero. This effect is generally reversible after cessation, though recovery takes months to over a year and is not guaranteed in all cases. Men of reproductive age who want to preserve fertility commonly use HCG (human chorionic gonadotropin) alongside TRT to maintain intratesticular testosterone and support spermatogenesis. This is a standard protocol modification at many TRT clinics.
How often is bloodwork needed on TRT?
Baseline bloodwork before starting TRT is considered essential — it establishes reference values for all key markers. The first follow-up panel is typically drawn at 6-8 weeks, timed as a trough draw immediately before the next injection. This captures the lowest point in the cycle and gives the most conservative measurement. After levels are stable and the dose is dialed in, ongoing monitoring every 3-6 months is the standard practice. Key markers to track include total and free testosterone, estradiol, hematocrit, PSA, lipids, and liver enzymes. Hematocrit warrants particular attention as testosterone-stimulated erythropoiesis is cumulative over time.